References
- Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunc-tional receptor-ligand pair. Adv Immunol 1996;61:1–77.
- Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792–5.
- Morimoto S, Kanno Y, Tanaka Y, Tokano Y, Hashimoto H, Jacquot S, et al. CD134L engagement enhances human B -cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L in-teractions coordinately regulate T cell-dependent B-cell responses. J Immunol 2000;164:4097–104.
- Tooze RM, Doody GM, Fearon DT. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by mem-brane immunoglobulin. Immunity 1997;7: 59–67.
- Smith KG, Fearon DT. Receptor modulators of B-cell receptor signalling - CD19/CD22. Curr Top Microbiol Immunol 2000;245: 195–212.
- Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regu-lates B lymphocyte signaling thresholds critical for the develop-ment of B-1 lineage cells and autoimmunity. J Immunol 1996;157: 4371–8.
- Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997;6: 107–18.
- Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256:105–7.
- Fujimoto M, Poe JC, Inaoki M, Tedder TF. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 1998;10:267–77.
- Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem 2000;275: 17420–7.
- Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997; 186:1923–31.
- Bourne T, Zukowska-Cooper M, Salaman MR, Seifert MH, Isenberg DA. Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following deple-tion of cells expressing CD19 or CD38. Clin Exp Immunol 1998; 111:611–6.
- Santiago ML, Mary C, Parzy D, Jacquet C, Montagutelli X, Parkhouse RM, et al. Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW x C57BL/6)F1 mice. Eur J Immunol 1998;28:4257–67.
- Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376: 352–5.
- Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnor-mal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction mol-ecule. Immunity 1995;3:39–50.
- Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quan-titative genetic variation in CD19 expression correlates with au-toimmunity. J Immunol 2000;165: 6635–43.
- Kiesel S, Pezzutto A, Haas R, Moldenhauer G, Dorken B. Func-tional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines. Immunology 1988;64: 445–50.
- Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modu-lation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 1999;11: 191–200.
- Tedder TF, Sato S, Poe JC, Fujimoto M. CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity. Keio J Med 2000;49:1–13.
- Anolik J, Campbell D, Felgar R, Rosenblatt J, Young F, Looney RJ. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE. Arthritis Rheum 2002;46 Suppl:546.
- Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Ftheumatol 1998;37:1334–7.